Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
Founded by serial entrepreneur Dinakara Nagalla, the platform enters the Indian market with 30,000 users, and 500 wellbeing professionals
Market grows 12.1%; volume contribution improves as 9 out of 10 key therapies post double-digit growth
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
Collaboration to deploy Philips’ IntelliBridge Enterprise platform across Bajaj Integrated Health System network, enabling seamless patient data flow and integrated care delivery.
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
